¹¬¾±ÉÏƤÄÚÁöÑù²¡±ä,Cervical intraepithelial neoplasiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ¾úÐÔÒõµÀ²¡,Bacterial vaginosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Âѳ²Ö×Áö,Ovarian neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉúÓýÆÚ,growth periodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢ÎÀÐDz»Îȶ¨,Microsatellite instabilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹¬¾±Ö×Áö,Cervix neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±»Òý·ÖÎö,citation analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ç»Òº,peritoneal fluidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×Ó¹¬ÄÚĤÖ×Áö,Endometrial neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×Ó¹¬¾±ÉÏƤÄÚÁö±ä,cervical intraepithelial neoplasiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏõËáß俵ßò,Miconazole nitrateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´àÐÔ×é°±ËáÈýÁªÌå,Fragile histidine triadÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔÚλÄÚĤ,Eutopic endometriumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·¼Ï㻯øÒÖÖƼÁ,aromatase inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹¬Ç»ÄÚÈ˹¤ÊÚ¾«,Intrauterine inseminationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Âѳ²´¢±¸¹¦ÄÜ,Ovarian reserveÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« RECK»ùÒò,RECK geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µâ»¯ÓÍ,LipiodolÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Âѳ²ÉÏƤ°©,epithelial ovarian cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÔ·´×ª,sex reversalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´×Ëá¼×ôÇÔÐͪ,medroxyprogesterone acetateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉúÖ³Ö§Ô­Ìå,Mycoplasma genitaliumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ͸Ã÷ϸ°û°©,Clear cell carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÎËá·ú¹ðÀûàº,Flunarizine HydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Âѳ²·´Ó¦ÐÔ,ovarian responseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±£ÊØÐÔÊÖÊõ,Conservative surgeryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ÙÉöÉÏÏÙƤÖÊËØÊͷż¤ËØ,Corticotropin-releasing hormoneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºËÐļÒÍ¥,nuclear familyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Âѳ²·´Ó¦,Ovarian responseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Skp2µ°°×,Skp2 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÅÅÂÑÂÊ,ovulation rateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿ØÖÆÐÔ³¬´ÙÅÅÂÑ,controlled ovarian hyperstimulationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« XȾɫÌåʧ»î,X chromosome inactivationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌåÖؼõÇá,Weight lossÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄæÁ÷,countercurrentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹¬¾±Ï¸°ûѧ,Cervical cytologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×Ó¹¬ÄÚĤÔöÉúÖ¢,endometrial hyperplasiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒìλÄÚĤ,Ectopic endometriumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HPV¸ÐȾ,HPV infectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²»Ã÷Ô­Òò²»ÔÐ,Unexplained infertilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒõµÀ¾úȺ,vaginal floraÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂÑÅÝÆÚ,Follicular PhaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Åèµ×¹¦ÄÜÕÏ°­,Pelvic floor dysfunctionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼×Ïõßò×¢ÉäÒº,Metronidazole injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂÈÃ×·Ò,clomipheneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Äò¼¤Ã¸ÐÍÏËÈÜøԭ¼¤»îÎïÊÜÌå,Urokinase-type plasminogen activator receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ÔÈ»ÖÜÆÚ,natural cycleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CYP1A1»ùÒò,CYP1A1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CD44v6,CD 44 v 6Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« À䶳ÅßÌ¥,frozen embryoÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Æ¢ÀÒ°±Ëἤø,spleen tyrosine kinaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« p15µ°°×,p15 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÂÉú¶ù½á¾Ö,Neonatal outcomeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´«µÝ²»Æ½ºâ¼ìÑé,Transmission disequilibrium testÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« AKTµ°°×,AKT proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ÆÌåÖ§³Ö,luteal supportÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´×Ëá»·±ûÔÐͪ,cyproterone acetateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³É±¾Ð§Ó÷ÖÎö,Cost-utility analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹ÃçÀչܼ¤ËØ,Anti-mullerian hormoneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒõµÀ×éÖ¯,Vaginal tissueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­·¢±Õ¾­,Primary amenorrheaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒõµÀÄîÖé¾ú²¡,vaginal candidiasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹¬¾±Õ³Òº,cervical mucusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄêÇḾŮ,Young womenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ËÁ£Ã¸»ùÒò,telomerase geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Leepµ¶,Leep knifeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ó«¹âԭλÔÓ½»(FISH),fluorescence in situ hybridization (FISH)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« GSTM1»ùÒò,GSTM1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏÙÉÏƤϸ°û,Glandular epithelial cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢Á£Ìå»·Ñõ»¯ÎïË®½âø,Microsomal epoxide hydrolaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸´·¢ÐÔÍâÒõÒõµÀÄîÖé¾ú²¡,recurrent vulvovaginal candidiasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×Ó¹¬ÄÚĤ¼äÖÊϸ°û,endometrial stromal cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊȸõËØA,chromogranin AÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö±³¦Ö×Áö/Õï¶Ï,rectal neoplasms/diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍâÒõÉÏƤÄÚ·ÇÁöÑù²¡±ä,nonneoplastic epithelial disorders of vulvaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÓÕµ¼ÅÅÂÑ,Ovulation inductionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÙ´²·ÖÀà,Clinical classificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾ø¾­ºóÒõµÀ³öѪ,Postmenopausal bleedingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÅèÇ»¼²²¡,Pelvic diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˹¤Êܾ«,Artificial inseminationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼×Ïõßò˨,metronidazole suppositoriesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˦·ÀÓùËØ-2,human ¦Â-defensin-2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²¡Àý±¨µÀ,case reportÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃÀ±¦´´ÃæËÙÓúÌù,MEBO Dressing for Accelerating Wound HealingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô¾­Á¿,Menstrual blood volumeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹¬¾±ð¤Òº,cervical mucusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÕ³¸½·Ö×Ó-1,Intercellular adhesion molecule-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« µÎ³æÒõµÀÑ×,trichomonal vaginitisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×óȲŵÔÐͪ¹¬ÄÚÊÍ·Åϵͳ,Levonorgestrel-releasing intrauterine systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÂÔ­Ìå¸ÐȾ,chlamydia infectionsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÇÖÏ®ÐÔѪ¹Üð¤ÒºÁö,aggressive angiomyxomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ú¿µßò½ºÄÒ,Fluconazole capsuleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍâÒõÁÛ״ϸ°û°©,Vulvar squamous cell carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µòÍö;¾¶,Apoptosis pathwayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñ¡ÔñÐÔÊäÂѹÜÔìÓ°Êõ,Selective salpingographyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ë¿°±Ëá/ËÕ°±Ëἤø,serine/threonine kinaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Å®ÐÔÐÔ¹¦ÄÜÕÏ°­,female sexual dysfunctionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PercollÌݶÈÀëÐÄ·¨,Percoll gradient centrifugationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ç°Í¥´óÏÙÄÒÖ×,Bartholin cystÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹¬¾±ÉÏƤÄÚÁö±ä(CIN),Cervical intraepithelial neoplasia(CIN)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
 1 2 3 4 5 6 7 8 ÉÏÒ»Ò³